Verici Dx plc (AIM:VRCI)
0.2000
-0.0050 (-2.44%)
Nov 6, 2026, 4:23 PM GMT
Verici Dx Revenue
Verici Dx had revenue of $1.77M USD in the half year ending June 30, 2026, a decrease of -46.96%. This brings the company's total for the last twelve months to $3.52M, up 84.11% year-over-year. In the year 2025, Verici Dx had annual revenue of $3.66M with 9.73% growth. That makes Verici Dx the 41,002nd largest company in the world by revenue and 796th in the United Kingdom.
Revenue (ttm)
$3.52M
Revenue Growth
+84.11%
P/S Ratio
3.01
Revenue / Employee
$153.13K
Employees
23
Market Cap
7.94M GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.66M | 325.00K | 9.73% |
| Dec 31, 2024 | 3.34M | 2.33M | 229.62% |
| Dec 31, 2023 | 1.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 46.99B |
| GSK plc | 33.54B |
| Haleon | 11.15B |
| Smith & Nephew | 4.77B |
| Palatin Technologies | 9.94M |
| Fusion Antibodies | 2.11M |
| Aptamer Group | 1.54M |
| CelLBxHealth | 1.15M |
Verici Dx News
- 5 weeks ago - Verici Dx Quarterly report: H1 2026 - Filings
- 4 months ago - Verici Dx Earnings Call Transcript: H2 2025 - Transcripts
- 4 months ago - Verici Dx Annual report: H2 2025 - Filings
- 4 months ago - Verici Dx Annual report: H2 2025 - Filings
- 4 months ago - Verici Dx Slides: H2 2025 - Filings
- 4 months ago - Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test - Business Wire
- 4 months ago - Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026 - Business Wire
- 5 months ago - CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients - Business Wire